RGEN
Repligen Corporation
Medical - Instruments & Supplies
Market Cap$7.45B
5Y Perf.+6.8%
Build Your Comparison
Side-by-side financial analysisRGEN
LLY
Try popular comparisons:
Stock Comparison
RGEN vs LLY
Revenue, margins, valuation, and 5-year total return — side by side.
LLY
Eli Lilly and Company
Drug Manufacturers - General
Market Cap$1.04T
5Y Perf.+568.9%
RGEN vs LLY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  RGEN |  LLY |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Drug Manufacturers - General |
| Market Cap | $7.45B | $1.04T |
| Revenue (TTM) | $763M | $72.25B |
| Net Income (TTM) | $51M | $25.27B |
| Gross Margin | 51.5% | 83.5% |
| Operating Margin | 8.7% | 45.9% |
| Forward P/E | 65.9x | 30.0x |
| Total Debt | $690M | $42.50B |
| Cash & Equiv. | $566M | $7.16B |
RGEN vs LLY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RGEN
LLY
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Repligen Corporation (RGEN) | 100 | 106.8 | +6.8% |
| Eli Lilly and Compa… (LLY) | 100 | 668.9 | +568.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RGEN vs LLY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LLY leads in 7 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
🥇LLY emerged as the overall leader. Track its performance:
RGEN
Repligen Corporation
The Defensive Pick
RGEN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.39, Low D/E 32.8%, current ratio 8.37x
Best for: sleep-well-at-night
LLY
Eli Lilly and Company
The Income Pick
LLY carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 11 yrs, beta 0.52, yield 0.5%
- Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
- 14.5% 10Y total return vs RGEN's 487.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  LLY | 44.7% revenue growth vs RGEN's 16.4% |
| Value | LLY | Lower P/E (30.0x vs 65.9x) |
| Quality / Margins | LLY | 35.0% margin vs RGEN's 6.7% |
| Stability / Safety | LLY | Beta 0.52 vs RGEN's 1.39 |
| Dividends | LLY | 0.5% yield; 11-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | LLY | +40.7% vs RGEN's +12.3% |
| Efficiency (ROA) | LLY | 22.7% ROA vs RGEN's 1.8%, ROIC 41.8% vs 2.2% |
RGEN vs LLY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
RGEN vs LLY — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLLYLAGGINGRGEN
RGENRepligen Corporation
0leads
LLYEli Lilly and Company
4leads
6 Total Categories
CATEGORYLEADERvs RGENMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LLY6/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LLY6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LLY6/6
Risk & VolatilityBeta, volatility, and downside exposure
LLY2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LLY leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LLY is the larger business by revenue, generating $72.2B annually — 94.6x RGEN's $763M. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to RGEN's 6.7%. On growth, LLY holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  RGENRepligen Corporat… | LLYEli Lilly and Com… |
|---|---|---|
| RevenueTrailing 12 months | $763M | $72.2B |
| EBITDAEarnings before interest/tax | $155M | $34.7B |
| Net IncomeAfter-tax profit | $51M | $25.3B |
| Free Cash FlowCash after capex | $104M | $13.6B |
| Gross MarginGross profit ÷ Revenue | +51.5% | +83.5% |
| Operating MarginEBIT ÷ Revenue | +8.7% | +45.9% |
| Net MarginNet income ÷ Revenue | +6.7% | +35.0% |
| FCF MarginFCF ÷ Revenue | +13.7% | +18.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.8% | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.0% | +169.9% |
LLY leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
Evenly matched — RGEN and LLY each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 47.8x trailing earnings, LLY trades at a 69% valuation discount to RGEN's 153.5x P/E. On an enterprise value basis, LLY's 34.3x EV/EBITDA is more attractive than RGEN's 54.7x.
| Metric | RGENRepligen Corporat… | LLYEli Lilly and Com… |
|---|---|---|
| Market CapShares × price | $7.4B | $1.04T |
| Enterprise ValueMkt cap + debt − cash | $7.6B | $1.07T |
| Trailing P/EPrice ÷ TTM EPS | 153.51x | 47.85x |
| Forward P/EPrice ÷ next-FY EPS est. | 65.91x | 30.00x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.66x |
| EV / EBITDAEnterprise value multiple | 54.72x | 34.32x |
| Price / SalesMarket cap ÷ Revenue | 10.09x | 15.92x |
| Price / BookPrice ÷ Book value/share | 3.55x | 37.16x |
| Price / FCFMarket cap ÷ FCF | 79.30x | 115.64x |
Evenly matched — RGEN and LLY each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
LLY leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $2 for RGEN. RGEN carries lower financial leverage with a 0.33x debt-to-equity ratio, signaling a more conservative balance sheet compared to LLY's 1.60x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs RGEN's 7/9, reflecting strong financial health.
| Metric | RGENRepligen Corporat… | LLYEli Lilly and Com… |
|---|---|---|
| ROE (TTM)Return on equity | +2.5% | +101.2% |
| ROA (TTM)Return on assets | +1.8% | +22.7% |
| ROICReturn on invested capital | +2.2% | +41.8% |
| ROCEReturn on capital employed | +2.2% | +46.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 8 |
| Debt / EquityFinancial leverage | 0.33x | 1.60x |
| Net DebtTotal debt minus cash | $124M | $35.3B |
| Cash & Equiv.Liquid assets | $566M | $7.2B |
| Total DebtShort + long-term debt | $690M | $42.5B |
| Interest CoverageEBIT ÷ Interest expense | 2.64x | 35.68x |
LLY leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LLY leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LLY five years ago would be worth $51,381 today (with dividends reinvested), compared to $6,690 for RGEN. Over the past 12 months, LLY leads with a +40.7% total return vs RGEN's +12.3%. The 3-year compound annual growth rate (CAGR) favors LLY at 35.1% vs RGEN's -4.4% — a key indicator of consistent wealth creation.
| Metric | RGENRepligen Corporat… | LLYEli Lilly and Com… |
|---|---|---|
| YTD ReturnYear-to-date | -19.7% | +2.0% |
| 1-Year ReturnPast 12 months | +12.3% | +40.7% |
| 3-Year ReturnCumulative with dividends | -12.7% | +146.7% |
| 5-Year ReturnCumulative with dividends | -33.1% | +413.8% |
| 10-Year ReturnCumulative with dividends | +487.5% | +1449.6% |
| CAGR (3Y)Annualised 3-year return | -4.4% | +35.1% |
LLY leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
LLY leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LLY is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than RGEN's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 92.8% from its 52-week high vs RGEN's 75.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RGENRepligen Corporat… | LLYEli Lilly and Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.39x | 0.52x |
| 52-Week HighHighest price in past year | $175.77 | $1182.73 |
| 52-Week LowLowest price in past year | $100.99 | $623.78 |
| % of 52W HighCurrent price vs 52-week peak | +75.1% | +92.8% |
| RSI (14)Momentum oscillator 0–100 | 64.5 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 2.6M |
LLY leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RGEN as "Buy" and LLY as "Buy". Consensus price targets imply 20.2% upside for RGEN (target: $159) vs 15.8% for LLY (target: $1271). LLY is the only dividend payer here at 0.55% yield — a key consideration for income-focused portfolios.
| Metric | RGENRepligen Corporat… | LLYEli Lilly and Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $158.67 | $1271.24 |
| # AnalystsCovering analysts | 24 | 45 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% |
| Dividend StreakConsecutive years of raises | — | 11 |
| Dividend / ShareAnnual DPS | — | $6.00 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
LLY leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallEli Lilly and Company (LLY)Leads 4 of 6 categories
Loading custom metrics...
RGEN vs LLY: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is RGEN or LLY a better buy right now?
For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.
7% revenue growth year-over-year, versus 16. 4% for Repligen Corporation (RGEN). Eli Lilly and Company (LLY) offers the better valuation at 47. 8x trailing P/E (30. 0x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RGEN or LLY?
On trailing P/E, Eli Lilly and Company (LLY) is the cheapest at 47.
8x versus Repligen Corporation at 153. 5x. On forward P/E, Eli Lilly and Company is actually cheaper at 30. 0x.
03Which is the better long-term investment — RGEN or LLY?
Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +413.
8%, compared to -33. 1% for Repligen Corporation (RGEN). Over 10 years, the gap is even starker: LLY returned +1450% versus RGEN's +487. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RGEN or LLY?
By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.
52β versus Repligen Corporation's 1. 39β — meaning RGEN is approximately 165% more volatile than LLY relative to the S&P 500. On balance sheet safety, Repligen Corporation (RGEN) carries a lower debt/equity ratio of 33% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.
05Which is growing faster — RGEN or LLY?
By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.
7% versus 16. 4% for Repligen Corporation (RGEN). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to 96. 0% for Eli Lilly and Company. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RGEN or LLY?
Eli Lilly and Company (LLY) is the more profitable company, earning 31.
7% net margin versus 6. 6% for Repligen Corporation — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 8. 1% for RGEN. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RGEN or LLY more undervalued right now?
On forward earnings alone, Eli Lilly and Company (LLY) trades at 30.
0x forward P/E versus 65. 9x for Repligen Corporation — 35. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGEN: 20. 2% to $158. 67.
08Which pays a better dividend — RGEN or LLY?
In this comparison, LLY (0.
5% yield) pays a dividend. RGEN does not pay a meaningful dividend and should not be held primarily for income.
09Is RGEN or LLY better for a retirement portfolio?
For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
52), 0. 5% yield, +1450% 10Y return). Both have compounded well over 10 years (LLY: +1450%, RGEN: +487. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RGEN and LLY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
LLY pays a dividend while RGEN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.